MARKET

NVCR

NVCR

Novocure
NASDAQ
75.98
-1.07
-1.39%
After Hours: 75.98 0 0.00% 17:00 09/30 EDT
OPEN
77.06
PREV CLOSE
77.05
HIGH
79.01
LOW
75.93
VOLUME
467.30K
TURNOVER
0
52 WEEK HIGH
124.35
52 WEEK LOW
56.39
MARKET CAP
7.96B
P/E (TTM)
-115.9469
1D
5D
1M
3M
1Y
5Y
Insider Sell: Novocure
Insider Sell: Novocure
MT Newswires · 1d ago
Novocure creates new CNS focused franchise to renew growth in brain cancer business
Oncology company Novocure (NASDAQ:NVCR) on Wednesday announced t...
Seekingalpha · 09/21 13:14
Novocure Announces Creation Of U.S. Central Nervous System Cancers Franchise Intended To Renew Focus On Growth In Glioblastoma Business; Frank Leonard Is Appointed As President
Frank Leonard is appointed President, CNS Cancers U.S.  Novocure (NASDAQ:NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources,
Benzinga · 09/21 12:09
Novocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business
ROOT, Switzerland, September 21, 2022--Novocure (NASDAQ: NVCR) today announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. This new organization will add resources, streamline decision-making and improve coordination across Nov...
Business Wire · 09/21 12:00
NovoCure Appears Poised for an Upside Breakout
NovoCure Ltd. is a commercial-stage oncology company that develops treatments for solid-tumor cancers. In this daily bar chart of NVCR, below, we can see that prices have traded sideways since December, building what I believe is a very impressive base. ...
TheStreet.com · 09/12 12:34
After losing 33% in the past year, NovoCure Limited (NASDAQ:NVCR) institutional owners must be relieved by the recent gain
If you want to know who really controls NovoCure Limited ( NASDAQ:NVCR ), then you'll have to look at the makeup of its...
Simply Wall St. · 09/12 10:12
Novocure to Participate in Upcoming Investor Conferences
ROOT, Switzerland, August 31, 2022--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 ...
Business Wire · 08/31 12:00
Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility
ROOT, Switzerland, August 10, 2022--On Tuesday, Aug. 9, U.S. Sen. Maggie Hassan (NH) joined members of Novocure’s leadership team to tour the company’s U.S. headquarters in Portsmouth, New Hampshire, and learn more about Novocure’s groundbreaking work to e...
Business Wire · 08/10 12:00
More
About NVCR
NovoCure Limited is an oncology company. The Company is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields therapy is a treatment that uses electric fields tuned to specific frequencies to disrupt cancer cell division. TTFields therapy is delivered through a portable medical device. Optune is approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA for the pathway for the treatment of malignant pleural mesothelioma (MPM) together with standard chemotherapies. It markets its products to United States, European Union, Germany, Japan and certain other countries.

Webull offers kinds of Novocure Ltd stock information, including NASDAQ:NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.